Advanced Thyroid Cancer
Showing 26 - 50 of >10,000
Thyroid Cancer Trial in Worldwide (Irofulven + capecitabine)
Completed
- Thyroid Cancer
- Irofulven + capecitabine
-
Aurora, Colorado
- +9 more
Jun 11, 2021
Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)
Recruiting
- Anaplastic Thyroid Cancer
- ATC
-
Shanghai, ChinaFudan University Affiliated Oncology Hospital
Dec 30, 2021
DTC - Differentiated Thyroid Cancer Trial in Beijing (Anlotinib HCl)
Recruiting
- DTC - Differentiated Thyroid Cancer
- Anlotinib hydrochloride
-
Beijing, ChinaPeking Union Medical College Hospital
Jan 18, 2022
Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)
Active, not recruiting
- Solid Tumor
- Medullary Thyroid Cancer
-
Guangzhou, Guangdong, China
- +12 more
May 9, 2022
Cancer, Solid Tumor, Melanoma Trial (KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose
Not yet recruiting
- Cancer
- +16 more
- KVA12123 - Dose Escalation
- +3 more
- (no location specified)
Feb 2, 2023
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma Trial in Shanghai (individualized mRNA
Not yet recruiting
- Adrenal Cortical Carcinoma
- +3 more
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
-
Shanghai, Shanghai, ChinaRuijin hospital, Shanghai Jiao-Tong University School of Medicin
Nov 19, 2023
Solid Tumor, Adult, Advanced Solid Tumor, Head Neck Cancer Trial in Irving, San Antonio, West Valley City (SNS-101 (anti-VISTA),
Recruiting
- Solid Tumor, Adult
- +19 more
- SNS-101 (anti-VISTA)
- Cemiplimab
-
Irving, Texas
- +2 more
May 24, 2023
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma Trial in
Recruiting
- Advanced Differentiated Thyroid Gland Carcinoma
- +102 more
- Cabozantinib S-malate
- Nivolumab
-
Chicago, Illinois
- +2 more
Apr 5, 2022
Advanced Cancer, Anal Carcinoma, Anal Cancer Trial in Worldwide (pembrolizumab)
Recruiting
- Advanced Cancer
- +24 more
- pembrolizumab
-
Los Angeles, California
- +21 more
Jan 18, 2023
Thyroid Cancer Trial in Beijing (Anlotinib HCl, Sodium Iodide I 131, Penpulimab)
Recruiting
- Thyroid Cancer
- Anlotinib hydrochloride
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
Jan 18, 2022
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer Trial in Spain
Recruiting
- Metastatic Thyroid Papillary Carcinoma
- +2 more
-
L'Hospitalet de Llobregat, Barcelona, Spain
- +14 more
Feb 18, 2022
Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer Trial in Israel, United States (CM-24 and Nivolumab - Dose
Recruiting
- Solid Tumor
- +6 more
- CM-24 and Nivolumab - Dose Escalation
- +4 more
-
Scottsdale, Arizona
- +10 more
Jan 17, 2023
Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer Trial in Tampa (Lenvatinib, Sorafenib, Cabozantinib)
Terminated
- Thyroid Cancer
- +5 more
- Lenvatinib
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jul 12, 2021
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer
Recruiting
- Thyroid Cancer
- NTRK fusion assessment
-
Roma, ItalyRegina Elena National Cancer Institute
Mar 31, 2023
Advanced Solid Tumor Trial in United Kingdom, United States (CDK-002)
Active, not recruiting
- Advanced Solid Tumor
- CDK-002
-
Scottsdale, Arizona
- +7 more
Sep 27, 2022
NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)
Recruiting
- Non-Small Cell Lung Cancer
- +2 more
-
Shanghai, Shanghai, China
- +1 more
Mar 17, 2022
Differentiated Thyroid Cancer Trial in Worldwide (Dabrafenib, Trametinib, Trametinib )
Recruiting
- Differentiated Thyroid Cancer
- Dabrafenib
- +3 more
-
Caba, Buenos Aires, Argentina
- +41 more
Nov 25, 2022
Differentiated Thyroid Cancer Trial in Nanjing, Peking (Apatinib Oral Tablet, Placebo Oral Tablet)
Active, not recruiting
- Differentiated Thyroid Cancer
- Apatinib Oral Tablet
- Placebo Oral Tablet
-
Nanjing, Jiangsu, China
- +1 more
Aug 9, 2021
s and Clinical Variables on Thyroid Cancer
Recruiting
- Thyroid Cancer
-
Milan, ItalyIstituto Auxologico Italiano, IRCCS
Mar 1, 2023